Pfizer Inc. $PFE Shares Purchased by Voya Investment Management LLC

Key Points

• Voya Investment Management LLC has increased its holdings in Pfizer Inc. by 5.0%, acquiring an additional 80,646 shares, bringing its total stake to 1,677,705 shares valued at approximately $42.5 million.
• Pfizer reported a strong quarterly performance, with an earnings per share (EPS) of $0.78, exceeding analysts' expectations of $0.58, and noted a revenue growth of 10.3% year-over-year.
• The company announced a quarterly dividend of $0.43 per share, representing an annualized dividend of $1.72 with a yield of 7.2%, though its payout ratio stands at 91.49%.

Voya Investment Management LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 5.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,677,705 shares of the biopharmaceutical company's stock after buying an additional 80,646 shares during the quarter. Voya Investment Management LLC's holdings in Pfizer were worth $42,513,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Howe & Rusling Inc. increased its position in Pfizer by 8.9% during the 1st quarter. Howe & Rusling Inc. now owns 28,800 shares of the biopharmaceutical company's stock valued at $730,000 after buying an additional 2,345 shares in the last quarter. Lynx Investment Advisory increased its position in Pfizer by 53.3% during the 1st quarter. Lynx Investment Advisory now owns 47,782 shares of the biopharmaceutical company's stock valued at $1,211,000 after buying an additional 16,621 shares in the last quarter. First Hawaiian Bank increased its position in Pfizer by 6.9% during the 1st quarter. First Hawaiian Bank now owns 54,455 shares of the biopharmaceutical company's stock valued at $1,380,000 after buying an additional 3,531 shares in the last quarter. Modern Wealth Management LLC grew its stake in Pfizer by 41.4% during the 1st quarter. Modern Wealth Management LLC now owns 44,785 shares of the biopharmaceutical company's stock valued at $1,135,000 after purchasing an additional 13,104 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its stake in Pfizer by 37.8% during the 1st quarter. Jones Financial Companies Lllp now owns 2,516,211 shares of the biopharmaceutical company's stock valued at $63,441,000 after purchasing an additional 690,259 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the topic of several research analyst reports. Morgan Stanley boosted their price target on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Bank of America boosted their price target on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Jefferies Financial Group boosted their price target on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Finally, Berenberg Bank lowered their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Price Performance

NYSE PFE traded down $0.95 during trading hours on Friday, reaching $23.91. The company's stock had a trading volume of 81,158,118 shares, compared to its average volume of 34,996,196. The firm has a market capitalization of $135.94 billion, a price-to-earnings ratio of 12.72, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company's 50-day moving average is $24.79 and its two-hundred day moving average is $24.28.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the prior year, the firm earned $0.60 earnings per share. The business's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. Pfizer's dividend payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.